About
Octimet Oncology NV develops targeted cancer therapies including OMO-1, a selective oral MET kinase inhibitor, and OMO-2, a dual MET and RAS pathway inhibitor, aimed at treating lung cancer and other oncology indications.
Explore Octimet's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.